Nivelles, Belgium — September 25, 2025
Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading institutions for cancer treatment, research, and education, and Quantoom Biosciences, a full-stack RNA technology partner have executed a non-exclusive research license and supply agreement to support the development of personalized cancer therapies using Quantoom’s proprietary lipid nanoparticle (LNP) formulation technology, Ncapsulate® QCX-002.
Under the agreement, MSK will use Ncapsulate QCX-002, an LNP delivery chemistry developed by Quantoom, for the research and development of personalized therapeutic products targeting human cancers. Under the agreement, Quantoom will supply QCX-002 to MSK directly to enable MSK’s R&D efforts. The agreement also includes an option to expand the license to future developments in Quantoom’s proprietary QCX library. Finally, MSK will further evaluate other RNA manufacturing technologies developed by Quantoom, paving the way for a potential broader collaboration in the field of RNA therapeutics.
At MSK, these efforts will be housed in The Olayan Center for Cancer Vaccines (OCCV), an academic biohub for personalized cancer immunotherapies. As part of the initial development phase, the OCCV at MSK will target deploying QCX-002 in at least one RNA medicine expected to enter Phase I clinical trials.
“This agreement with MSK marks a major milestone for Quantoom and validates the potential of our QCX formulation chemistries in human therapeutic applications,” said José Castillo, CEO of Quantoom Biosciences. “It is an honor to collaborate with one of the most prestigious cancer research institutions in the world to help advance personalized RNA-based medicines.”
“We are thrilled to partner with Quantoom to advance personalized therapeutics for patients battling deadly cancers,” said Vinod Balachandran, MD, Director of the OCCV at MSK. “The powerful union of cutting-edge innovation and deep expertise, such as this, is precisely what’s needed to accelerate the development of breakthrough cancer medicines.
